Compare · BIIB vs FENC
BIIB vs FENC
Side-by-side comparison of Biogen Inc. (BIIB) and Fennec Pharmaceuticals Inc. (FENC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and FENC operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.68B, about 95.4x FENC ($300.5M).
- Over the past year, BIIB is up 46.0% and FENC is up 6.0% - BIIB leads by 40.1 points.
- FENC has been more active in the news (16 items in the past 4 weeks vs 11 for BIIB).
- BIIB has more recent analyst coverage (25 ratings vs 5 for FENC).
- Company
- Biogen Inc.
- Fennec Pharmaceuticals Inc.
- Price
- $194.31-2.44%
- $8.71-0.85%
- Market cap
- $28.68B
- $300.5M
- 1M return
- -1.88%
- +22.61%
- 1Y return
- +46.03%
- +5.96%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 11
- 16
- Recent ratings
- 25
- 5
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Latest BIIB
- Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: Biogen Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Biogen upgraded by Needham with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
- EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
- Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
- UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
Latest FENC
- SEC Form 4 filed by Director Brughera Marco Maria
- SEC Form 4 filed by Director Cook Jodi A
- SEC Form 4 filed by Director Islam Khalid
- SEC Form 4 filed by Director Rallis Chris A
- Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Fennec Announces Results of Annual Meeting
- Director Raykov Rosty was granted 2,778 shares, exercised 15,597 shares at a strike of $2.45 and sold $93,766 worth of shares (9,747 units at $9.62) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 130,079 units (SEC Form 4)
- Chief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.65% to 24,176 units (SEC Form 4)
- Chief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 62,825 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.59% to 289,269 units (SEC Form 4)